Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab

Article

Abstract: Objectives: COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on matur

Palabras claves:

CD6, covid-19, Cytokine release syndrome, Itolizumab, Monoclonal antibody, SARS-COV2

Autores:

Arencibia M., Betancourt J., Caballero A., Cabrera L., Castillo U., Cepeda M., Despaigne R.E., Diaz H., Domecq M., Escalona A., Estevez D., Filgueira L.M., García Y., Hidalgo C.J., Leon K., Lorenzo G., Lorenzo P., Martinez A., Mazorra Z., Meriño E., Ortega L.M., Ramírez A., Ramos M., Saavedra Hernández D., Sánchez L., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.

Fuentes:

scopus